Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Morgan, R.A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006).
Heslop, H.E. et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2, 551–555 (1996).
Bollard, C.M. et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus–positive Hodgkin's disease. J. Exp. Med. 200, 1623–1633 (2004).
Khanna, R., Moss, D. & Gandhi, M. Technology insight: applications of emerging immunotherapeutic strategies for Epstein-Barr virus–associated malignancies. Nat. Clin. Pract. Oncol. 2, 138–149 (2005).
Blattman, J.N. & Greenberg, P.D. Cancer immunotherapy: a treatment for the masses. Science 305, 200–205 (2004).
Leen, A.M., Rooney, C.M. & Foster, A.E. Improving T cell therapy for cancer. Annu. Rev. Immunol. 25, 243–265 (2007).
Sadelain, M., Riviere, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35–45 (2003).
Stauss, H.J. et al. Monoclonal T cell receptors: new reagents for cancer therapy. Mol. Ther. 15, 1744–1750 (2007).
Park, J.R. et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15, 825–833 (2007).
Kershaw, M.H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115 (2006).
O'Reilly, R.J. et al. Adoptive transfer of antigen-specific T cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol. Res. 38, 237–250 (2007).
Bollard, C.M. et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T lymphocyte transfer. Blood 110, 2838–2845 (2007).
Straathof, K.C. et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes. Blood 105, 1898–1904 (2005).
Leen, A.M. et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12, 1160–1166 (2006).
Rossig, C., Bollard, C.M., Nuchtern, J.G., Rooney, C.M. & Brenner, M.K. Epstein-Barr virus–specific human T lymphocytes expressing antitumor chimeric T cell receptors: potential for improved immunotherapy. Blood 99, 2009–2016 (2002).
Heemskerk, M.H. et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J. Exp. Med. 199, 885–894 (2004).
Savoldo, B. et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T cell receptor for immunotherapy of Hodgkin disease. Blood 110, 2620–2630 (2007).
Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263–274 (2005).
Rabinovich, G.A., Gabrilovich, D. & Sotomayor, E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267–296 (2007).
Berger, C. et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294–305 (2008).
Rooney, C.M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus–induced lymphoma in allogeneic transplant recipients. Blood 92, 1549–1555 (1998).
Rossig, C. et al. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T cell responses via chimeric T cell receptors. J. Immunother. 29, 21–31 (2006).
Krance, R.A. et al. Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol. Blood Marrow Transplant. 9, 273–281 (2003).
Wahl, S.M., Wen, J. & Moutsopoulos, N. TGF-β: a mobile purveyor of immune privilege. Immunol. Rev. 213, 213–227 (2006).
Hunder, N.N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698–2703 (2008).
Gattinoni, L., Powell, D.J., Jr, Rosenberg, S.A. & Restifo, N.P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6, 383–393 (2006).
Smyth, M.J., Dunn, G.P. & Schreiber, R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90, 1–50 (2006).
Zitvogel, L., Tesniere, A. & Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6, 715–727 (2006).
Fisher, B. et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. 7, 250–261 (1989).
Maher, J., Brentjens, R.J., Gunset, G., Riviere, I. & Sadelain, M. Human T lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor. Nat. Biotechnol. 20, 70–75 (2002).
Stephan, M.T. et al. T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13, 1440–1449 (2007).
Brentjens, R.J. et al. Eradication of systemic B cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279–286 (2003).
Mescher, M.F. et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol. Rev. 211, 81–92 (2006).
Cooper, L.J. et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 105, 1622–1631 (2005).
Jaffe, C.C. Measures of response: RECIST, WHO, and new alternatives. J. Clin. Oncol. 24, 3245–3251 (2006).